Zoetis (ZTS) closed at $125.32, down 1.45% from the prior day, while the S&P 500 gained 0.16%, the Dow rose by 0.17%, and the Nasdaq increased by 0.26%. Shares of Zoetis have grown by 7.17% in the past month, outperforming the Medical sector and S&P 500.

Investors are awaiting Zoetis’ earnings release on February 12, 2026, with projected earnings of $1.4 per share and revenue of $2.36 billion, up 1.89% from the previous year. Analysts suggest positive estimate revisions reflect optimism about the company’s future performance.

Zoetis currently holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 18.78, higher than the industry average. The company’s PEG ratio is 2.59, indicating the stock may be trading at a premium. The Medical – Drugs industry ranks in the top 30% of all industries.

Looking for investment opportunities? Check out Zacks’ report on 5 Stocks Set to Double, handpicked by experts as potential gainers. Past recommendations have seen significant growth, offering an opportunity to discover under-the-radar stocks poised for success.

Read more at Nasdaq: Zoetis (ZTS) Stock Dips While Market Gains: Key Facts